Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Despite the limitations and paucity of data, the most comprehensive review of visceral leishmaniasis to date in pregnant women and vertical transmission of leishmaniasis has confirmed that liposomal amphotericin B is the safest treatment option and it is critical to ensure access to this.

Indian woman holding a newborn baby © Credit: Rama George-Alleyne, World Bank

This systematic review by Prabin Dahal and colleagues found that reports on the occurrence of Visceral Leishmaniasis (VL) in pregnant women are rare in published literature, are not systematically captured, and cases are rarely followed-up to detect the consequences of infection and treatment on the pregnant woman and foetus.

The review identifies reported cases and assesses the risk-benefit balance of antileishmanial therapies to the pregnant woman and the child. It brings together scattered observations of VL in pregnant women in the clinical literature and highlights that the disease in pregnancy is under-reported and under-studied. The authors found that information was often incomplete and it was difficult to derive generalisable information on outcomes, however, the findings suggest that liposomal amphotericin B (L-AmB) should be the preferred treatment for VL during pregnancy.

In practice, pregnant and lactating women are regularly excluded from clinical studies and are considered “therapeutic orphans”. Existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males while, substantially less is known about the optimal treatment response in female patients. This means that existing therapeutic guidelines regarding drug usage in pregnancy are guided by limited evidence generated from case reports and small case series

Better understanding of the treatment of VL in pregnancy is important because of the severe impact of VL on pregnant women in low-income settings.

The full story is available on the IDDO website

Read the publication Visceral Leishmaniasis in pregnancy and vertical transmission: A systematic literature review on the therapeutic orphans, on the PLOS Neglected Tropical Diseases website

Similar stories

Tropical Medicine DPhil Students awarded NDM Prize

Every year, the Nuffield Department of Medicine awards NDM Prizes to our most outstanding students. This year, Mo yin and Rebecca Inglis (both at MORU) were highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student, and Mohammad Ali (OCGHR) as second year DPhil student. Our warmest congratulations to you all!

New study alerts to the risk of poor quality medicines used to prevent and treat cardiovascular disease

There are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.

Systematic review identifies research gaps for Chagas disease

A new, large-scale systematic review published in PLOS Neglected Tropical Diseases has identified clear, significant research gaps in the diagnosis and treatment of Chagas disease. The paper also highlights significant differences in study design, diagnostic methods, duration of follow-up, and the timing of outcome assessment used by investigators even in the last decade.

RECOVERY Trial announced as overall winner of Best COVID-19 Response Project Award in the UK

The RECOVERY Trial has won the Project Management Institute’s Special Covid-19 UK Response Project Award. The award specifically recognised RECOVERY’s work to investigate whether the cheap steroid dexamethasone was an effective treatment for patients hospitalised with severe COVID-19.

ISARIC COVID-19 clinical database passes ½ million patient records mark

COVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.

RECOVERY Trial named joint winner of HDR UK’s Impact of the Year Award

The RECOVERY trial has been jointly awarded Health Data Research UK’s 2021 Impact of the Year Award. This award is open to projects which had effectively used health data to improve people’s lives, including through clinical practice, policy, software, algorithms, or publications. The award was presented by James O’Shaughnessy at HDR UK’s online Annual Scientific Conference: Data Insights in a Pandemic.